dAAO is primarily active in the cerebellum, small intestine, liver, and kidney, and it is hypothesized that a dAAO inhibitor may be beneficial in schizophrenia via reduced peripheral degradation of d-serine rather than by direct cortical activity. The gene discussed is DAO; the disease is schizophrenia.